We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
News - Cellvizio - Oct 22, 2019

Evaluating interventional pulmonology as the next value driver

Provided below is a newly published company note authored by goetzpartners securities Limited discussing our 510(k) clearance for the use of Cellvizio in the field of interventional pulmonology. 

This report highlights how interventional pulmonology represents a promising commercial opportunity based on (1) a large market with a vast clinical need, (2) Cellvizio's unique ability to facilitate biopsy guidance and in vivo characterization, and (3) first mover advantage with a well differentiated product that is compatible with conventional bronchoscopes, emerging endoluminal robotic platforms as well as existing advanced navigational bronchoscopy platforms.


Disclaimer
Please note that this Equity Research publication is for Institutional Investor / Professional Investor use only and is not intended for Retail / Private client use. Any opinions, estimates or forecasts regarding Mauna Kea Technologies, S.A.’s performance made by goetzpartners securities Limited analysts are theirs alone and do not represent opinions, forecasts or predictions of Mauna Kea Technologies, S.A. or its management.